Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease

Feng Shiun Shie, Randall L. Woltjer

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Alzheimer's disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-antyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia-mediated neurainflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.

Original languageEnglish (US)
Pages (from-to)2865-2871
Number of pages7
JournalCurrent Medicinal Chemistry
Issue number27
StatePublished - Nov 2007


  • Alzheimer's disease
  • Beta-amyloid
  • Microglial activation
  • Neuroinflammation
  • Tau
  • Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this